Investment
Features
FeesSafety
Academy
More
Pluang+

Compare Alnylam Pharmaceuticals, Inc. (ALNY) vs Boston Beer Company Inc (SAM) Price & Performance

Alnylam Pharmaceuticals, Inc.Trade
Boston Beer Company IncTrade

Price performance (Past 24H)

Key statistics

Alnylam Pharmaceuticals, Inc. vs Boston Beer Company Inc — how do they compare? Alnylam Pharmaceuticals, Inc. trades at $221.2 (market cap $29.03B), while Boston Beer Company Inc trades at $177.2 (market cap $1.86B). The key difference: Alnylam Pharmaceuticals, Inc. is far larger — about 15.6× Boston Beer Company Inc's market cap, and Boston Beer Company Inc is trading nearer its 52-week high, Alnylam Pharmaceuticals, Inc. nearer its low. Which is the better fit depends on your goals.

ALNYSAM
Market Cap
$29.03B$1.86B
Sector
HealthConsumer Staples
52-Week High
$491.22$260.05
52-Week Low
$205.48$161.08
Enterprise Value
$26.99B$1.63B

Aura AI Summary

Signals from Pluang's Aura AI — not financial advice

Alnylam Pharmaceuticals, Inc.

ALNY trades at $219.20, down 1.43% amid bearish technical signals and recent earnings volatility. The stock faces near-term pressure from a Q2 2026 EPS miss and lowered 2026 sales guidance, but maintains strong fundamentals with 2025 revenue of $3.71B and net income of $313.75M. Analyst consensus remains bullish with a $370.07 price target, though multiple law firms are investigating potential securities fraud as reported by PRNewsWire and GlobeNewsWire in early August 2026.

Outlook is mixed: robust revenue growth and high profitability margins support long-term potential, but legal uncertainties and recent earnings disappointments pose significant risks. The stock's current valuation (P/E 38.19) reflects growth expectations, yet investor caution is warranted given technical bearishness and ongoing investigations.

Boston Beer Company Inc

The Boston Beer Company (SAM) trades at $186.61, up 1.94% on the day, with a bullish technical signal driven by moving averages. The stock shows mixed fundamentals; while the P/E ratio of 22.66 and P/S of 0.99 suggest reasonable valuation, recent quarterly earnings have missed expectations, and the company faces volume declines in core brands. Positive cash flow and innovation in ready-to-drink products provide some offset. Analyst sentiment is cautious, with a consensus price target of $207.33 but a majority hold rating.

Outlook: Upside exists if new product growth accelerates and margins improve, but risks from weak demand and competitive pressure persist. The stock's trajectory hinges on reversing volume trends and achieving future earnings targets, making it a hold for now with watchful optimism.

Returns comparison

Trailing returns across standard periods

Top news

Latest headlines on both assets

About Alnylam Pharmaceuticals, Inc.

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has five drugs on the market: Onpattro and Amvuttra for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia.

Read more on ALNY

About Boston Beer Company Inc

Boston Beer is a leader in U.S. high-end malt beverages and adjacent categories, with strong positions in craft beer, hard cider, and hard seltzer. The firm sells an array of flavor variants and package sizes, predominantly centered around four priority brands: Samuel Adams, Angry Orchard, Twisted Tea, and Truly Hard Seltzer. Its drinks are produced in both company-owned breweries as well as through third-party contract arrangements, and while the company primarily goes to market through independent wholesalers (as mandated by law), it operates a fairly large salesforce to induce demand across the value chain (distributors, retailers, and drinkers). The preponderance of revenue is generated domestically.

Read more on SAM